Endotype Prevalence in Unilateral Nasal Polyps

Abstract

ABSTRACT Aim: In this study, the endotypes of patients with unilateral nasal polyp in our clinic were researched by dividing into type 2 and non-type 2 disease. Material and Method: A total of 50 patients (35 men, 15 women; mean age 48.8 years, range 16-73) attending our clinic and operated due to unilateral nasal polyp from March 2020 to March 2023 were retrospectively investigated. Patients were divided into two groups according to pathology reports: group 1 included patients with type 2 according to endotype dominance and group 2 included patients with non-type 2 dominance. Results: Of the 50 patients investigated with unilateral nasal polyp, 46% were in group 1 and 54% were in group 2. The mean age in group 1 was 48.9 years, while the mean age in group 2 was 48.3 years. In group 1, 19 patients were men (82.6%) and 4 were women (17.3%). In group 2, 16 patients were men (59.2%) and 11 were women (40,7%). There was no statistically significant difference between the two groups in terms of sex and age (p=0.13, p=0.97, respectively). Conclusion: In our study, 46% of patients were in group 1, while 54% were in group 2. These rates are different from the rates in endotype studies published in western societies. Performing larger prospective studies in our region and different regions will be beneficial to determine more accurate strategies for treatment and monitoring.

Keywords

• Nasal polyp
• endotype
• chronic rhinosinusitis

Tek Taraflı Nazal Poliplerde Endotip Prevalansı

Abstract

ÖZET Amaç: Bu çalışmada kliniğimizdeki tek taraflı nazal polip hastaları endotiplerine göre tip 2 ve tip 2 dışı hastalık şeklinde ayrılarak oranlar araştırıldı. Materyal ve Metot: Mart 2020- Mart 2023 yılları arasında tek taraflı nazal poliple kliniğimize başvuran ve nazal polip nedeniyle ameliyat edilen toplam 50 hasta (35 erkek, 15 kadın, ortalama yaş 48,8, dağılım 16-73) retrospektif olarak incelendi. Hastalar patoloji raporlarına göre iki gruba ayrıldı: endotip baskınlığına göre tip 2 olan hastalar grup 1, tip 2 dışı olan hastalar grup 2 olarak ele alındı. Bulgular: Tek taraflı nazal poliple incelenen 50 hastanın %46’sı grup 1, %54’ü grup 2 olarak izlendi. Grup 1’in yaş ortalaması 48,9 iken, Grup 2’nin yaş ortalaması 48,3 idi. Grup 1’deki hastaların 19’u (%82,.6) erkek, 4’ü (%17,3) kadın idi. Grup 2’de ise hastaların 16’sı (%59,2) erkek, 11’i (%40,7) kadın idi. Gruplar arası cinsiyet ve yaş özellikleri açısından anlamlı istatistiksel fark izlenmedi.(sırayla p=0,13 ve p=0,97) Sonuç: Çalışmamızda hastaların yüzde 46’sı grup 1 olarak izlenirken yüzde 54’ü grup 2 olarak izlendi. Bu oranlar batı toplumunda yayınlanan endotip çalışmalarındaki oranlardan farklı izlendi. Bölgemiz ve farklı bölgeler için daha geniş ve prospektif çalışmalar yapılması tedavi ve takip konusunda daha doğru stratejilerin belirlenmesinde faydalı olacağı düşünülmektedir.

Keywords

• Endotip
• nazal polip
• kronik rinosinüzit

References

1. 1. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, Toppila-Salmi S, Bernal-Sprekelsen M, Mullol J, Alobid I, Anselmo-Lima WT. European position paper on rhinosinusitis and nasal polyps 2020. doi:10.4193/rhin20.601
2. 2. Yong Lee J. Unilateral paranasal sinus diseases: analysis of the clinical characteristics, diagnosis, pathology, and computed tomography findings. Acta oto-laryngologica. 2008 Jan 1;128(6):621-6. doi:10.1080/00016480701663417
3. 3. Gomez JA, Mendenhall WM, Tannehill SP, Stringer SP, Cassisi NJ. Radiation therapy in inverted papillomas of the nasal cavity and paranasal sinuses. American journal of otolaryngology. 2000 May 1;21(3):174-8. doi:10.1016/S0196-0709(00)85020-6
4. 4. Ahern S, Cervin A. Inflammation and endotyping in chronic rhinosinusitis—a paradigm shift. Medicina. 2019 Apr 5;55(4):95. doi:10.3390/medicina55040095
5. 5. Commins SP, Borish L, Steinke JW. Immunologic messenger molecules: cytokines, interferons, and chemokines. Journal of Allergy and Clinical immunology. 2010 Feb 1;125(2):S53-72. doi:10.1016/j.jaci.2009.07.008
6. 6. Mucida D, Salek-Ardakani S. Regulation of TH17 cells in the mucosal surfaces. Journal of Allergy and Clinical Immunology. 2009 May 1;123(5):997-1003. doi:10.1016/j.jaci.2009.03.016
7. 7. Li X, Meng J, Qiao X, Liu Y, Liu F, Zhang N, Zhang J, Holtappels G, Luo B, Zhou P, Zheng Y. Expression of TGF, matrix metalloproteinases, and tissue inhibitors in Chinese chronic rhinosinusitis. Journal of Allergy and Clinical Immunology. 2010 May 1;125(5):1061-8. doi:10.1016/j.jaci.2010.02.023
8. 8. Zhang N, Van Zele T, Perez-Novo C, Van Bruaene N, Holtappels G, DeRuyck N, Van Cauwenberge P, Bachert C. Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease. Journal of Allergy and Clinical Immunology. 2008 Nov 1;122(5):961-8.doi:10.1016/j.jaci.2008.07.008

9. 9. Zhang N, Holtappels G, Claeys C, Huang G, Van Cauwenberge P, Bachert C. Pattern of inflammation and impact of Staphylococcus aureus enterotoxins in nasal polyps from southern China. American journal of rhinology. 2006 Jul;20(4):445-50. doi:10.2500/ajr.2006.20.2887
10. 10. Ba L, Zhang N, Meng J, Zhang J, Lin P, Zhou P, Liu S, Bachert C. The association between bacterial colonization and inflammatory pattern in Chinese chronic rhinosinusitis patients with nasal polyps. Allergy. 2011 Oct;66(10):1296-303. doi:10.1111/j.1398-9995.2011.02637.x
11. 11. Wu Q, Yuan L, Qiu H, Wang X, Huang X, Zheng R, Yang Q. Efficacy and safety of omalizumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis of randomised controlled trials. BMJ open. 2021 Sep 1;11(9):e047344. doi:10.1136/bmjopen-2020-047344
12. 12. Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, Hellings P, Jiao L, Wang L, Evans RR, Pirozzi G. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. Jama. 2016 Feb 2;315(5):469-79. doi:10.1001/jama.2015.19330
13. 13. Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, Mullol J, Greos LS, Bosso JV, Laidlaw TM, Cervin AU. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. The Lancet. 2019 Nov 2;394(10209):1638-50. doi:10.1016/S0140-6736(19)31881-1